study in patients with actinic keratosis (an disease of the skin) with the aim to evaluate the efficacy, the safety and the pharmacokinetics (way the body absorbs, distributes, and gets ride of the drug) of LFX453 after multiple applications to the skin • To assess tolerability and safety of topical LFX453 formulations in patients with actinic keratosis (AK) • To assess efficacy of topical LFX453 formulations in treating AK compared to vehicle afte...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A multicenter, double-blind, randomized, parallel-group study to evaluate the safety, tolerability, and efficacy of once daily amlodipine/valsartan 5/80mg as compared to amlodipine/valsartan 5/40mg or to amlodipine 5mg once daily in elderly patients with essential hypertension not adequately controlled after four weeks on amlodipine 5mg once daily The primary objective of this trial is to evaluate the overall safety and tolerability profile of a regimen of amlodipine/valsartan 5/80 mg as compared to a regimen of amlodipine/valsartan 5/40 mg (wi...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A randomized, double-blind study to assess the safety and efficacy of different dose levels of Pasireotide (SOM230) s.c. over a 6 month treatment period in patients with de novo, persistent or recurrent Cushing’s disease To assess the efficacy in terms of response to pasireotide 600 μg s.c. b.i.d. and 900 μg s.c. b.i.d. independently in patients with Cushing’s disease as measured by UFC ≤1.0 X ULN from baseline after ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Efficacy in Reducing Fractures and Safety of Zoledronic Acid in Men With Osteoporosis This study will investigate if the drug zoledronic acid given once yearly is safe and has beneficial effects in treating osteoporosis by reducing bone loss and fractures in men with osteop...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A multi-center, randomized, double-blind clinical trial to evaluate the safety and tolerability of 24 weeks treatment with vildagliptin (50 mg qd) versus placebo in patients with type 2 diabetes and moderate or severe renal insufficiency To evaluate the safety and tolerability of vildagliptin (50 mg qd) vs. placebo in patients with T2DM and moderate or severe renal insufficiency over 24 weeks of treatment.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

randOmized stUdy using acceleromeTry to compare Sacubitril/valsarTan and Enalapril in Patients with Heart Failure (OUTSTEP-HF) To assess changes in daily non-sedentary daytime activity between baseline and after 12 weeks of treatment in sacubitril/valsartan vs. enalapril treated patients.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

The impact of omalizumab treatment in UK clinical practice for asthma Background and study aims Allergic asthma is the most common type of asthma, where symptoms such as coughing, wheezing, chest tightness and breathlessness begin when the body reacts to something it is...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Étude PZPX2203 : étude de phase 2 évaluant l’efficacité du pazopanib chez des enfants, adolescents et jeunes adultes ayant des tumeurs solides récidivantes ou réfractaires. [essai clos aux inclusions] Les tumeurs solides peuvent se développer dans n’importe quel tissu : peau, muqueuses, os, organes, etc. Ce sont les plus fréquentes puisqu’à elles seules, elles représentent 90 % des cancers humains....

• Pays France
• Organes Sarcomes, Primitif du foie, Cerveau, Os
• Spécialités Thérapies Ciblées, Pédiatrie

A multicenter, randomized, open label, parallel-group phase IIB study on the efficacy and safety of oral regimens of DEB025 alone or in combination with ribavirin versus Standard of Care (peg-IFNα2a plus ribavirin) in treatment-naïve hepatitis C genotype 2 and 3 patients To evaluate the proportion of patients who achieve RVR with DEB025 600mg QD plus RBV 400 mg BID, DEB025 800 mg QD plus RBV 400 mg BID and DEB025 1000 mg QD treatment groups, in treatment-naïve chronic...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Study in patients with moderate to severe psoriasis to assess efficacy and safety of secukinumab To demonstrate that 300 mg secukinumab administered every 2 weeks is superior in achieving PASI 90 at week 32 compared to 300 mg secukinumab every 4 weeks in patients who after treatment with the stan...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune